Acalabrutinib is a highly selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK), and is being considered for use in the treatment of relapsed chronic lymphoid leukemia. Mutations in BTK result in a variety of B-cell related malignancies, as it upsets the B cell's signalling pathways.
|References||Wu, J., Zhang, M., & Liu, D. (2016). Acalabrutinib (ACP-196): A selective second-generation BTK inhibitor. Journal of Hematology & Oncology, 9(1). doi:10.1186/s13045-016-0250-9|